Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension study of Emrusolmin in multiple system atrophy
MOH_2026-01-27_015621Phase 2Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emrusolmin in multiple system atrophy (MSA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety. Started Jan 2026; status: recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on MOH_2026-01-27_015621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-27_015621.